H2BC3

Across TCGA pan-cancer cohorts, H2BC3 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated H2BC3 data layer compared with 4 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher H2BC3 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated H2BC3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and ACC show a favorable association.

LIHC, THCA, and LGG are the cancer types where H2BC3 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	III,IV	0.410	0.749	<.001	62	view →
THCA	OS	Tertile	All	0.953	0.987	.004	57	view →
LGG	DFS	Tertile	All	0.335	0.465	<.001	36	view →
UVM	OS	Tertile	All	0.368	0.763	.008	27	view →
ESCA	OS	Quartile	All	0.615	0.870	.002	27	view →
SARC	OS	Tertile	All	0.622	0.802	<.001	22	view →
LUAD	DFS	Median	II,III,IV	0.442	0.143	.002	21	view →
UCS	DFS	Median	IV	0.440	0.885	.015	18	view →
LUSC	OS	Quartile	III,IV	0.208	0.477	.011	14	view →
ACC	DFS	Tertile	IV	0.659	0.108	.017	13	view →
KIRC	OS	Quartile	II,III,IV	0.646	0.840	.007	12	view →
BLCA	OS	Median	III,IV	0.424	0.155	.016	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

H2BC3–LIHC (OS)

Open the LIHC breakdown →